Gateway to Think Tanks
来源类型 | Dissertations |
规范类型 | 其他 |
DOI | https://doi.org/10.7249/RGSD422 |
来源ID | RGSD-422 |
Three Essays in Health Economics: Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments | |
Jakub P. Hlavka | |
发表日期 | 2018 |
出版年 | 2018 |
页码 | 55 |
语种 | 英语 |
摘要 | The emergence of high-cost treatments has accelerated the pace of discussions about alternative payment models that would simultaneously enable rapid patient access while ensuring sustainable health care spending. However, limited empirical research exists on the magnitude of the problem and the expected performance of such payment models. The first paper presents a pipeline analysis of regenerative treatments in clinical trials. It finds that there are nearly 50 late-stage clinical trials that could produce regenerative drugs with potentially high prices. Alzheimer's disease poses the largest budget impact risk for U.S. payers, with new spending likely to exceed $50 billion annually. Spending on several other regenerative treatments, including treatments for traumatic brain injury, X-linked retinoschisis and congestive heart failure, could each exceed $5 billion annually. The second paper studies a novel payment model linking a drug's performance to pre-negotiated price levels. Drawing on the Future Elderly Model (FEM), it estimates the clinical benefits of PCSK9 inhibitors under three different efficacy scenarios. It shows that an adaptive pricing approach has the potential to lower the cost per event avoided under a low-efficacy scenario, thus avoiding unnecessary spending, should the drug not meet clinical trial efficacy in the real world. The third paper studies deferred payment in a gene therapy for congestive heart failure. It draws on a simulation of more than 91,000 Medicare fee-for-service beneficiaries over a period of 3 years and finds that deferred payment results in a 26.1% reduction of cardiovascular admissions and a 23.3% reduction of deaths over a three-year period, both relative to status quo payment and assuming a fixed budget constraint. Financial gains to payers and manufacturers are relatively minimal, with savings on avoided admissions amounting to just 0.3% of total spending, primarily due to the small share of expected cost savings on the total cost of therapy. The dissertation finds that large budget pressures resulting from regenerative treatments will be driven by several specific indications, and tests how two different payment models could help address the uncertainty about clinical benefits and the high upfront cost of some emerging therapies. |
目录 | Table of Contents
|
主题 | Health Care Payment Approaches ; Health Economics |
URL | https://www.rand.org/pubs/rgs_dissertations/RGSD422.html |
来源智库 | RAND Corporation (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/112015 |
推荐引用方式 GB/T 7714 | Jakub P. Hlavka. Three Essays in Health Economics: Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments. 2018. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
x1545054548912.jpg(4KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
RAND_RGSD422.pdf(531KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[Jakub P. Hlavka]的文章 |
百度学术 |
百度学术中相似的文章 |
[Jakub P. Hlavka]的文章 |
必应学术 |
必应学术中相似的文章 |
[Jakub P. Hlavka]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。